3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
3
Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Kidney Neoplasms
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Endocrine Gland Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
14
Nivolumab
11
Ipilimumab
10
cabozantinib
6
Axitinib
6
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Biopsy, Large-Core Needle
×
1 year
×
Clear all
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled